Sarepta down analysts flag risks after second Elevidys-linked death

Published 16/06/2025, 13:44
Updated 16/06/2025, 13:54
© Reuters

Investing.com -- BMO Capital and Piper Sandler downgraded Sarepta Therapeutics (NASDAQ:SRPT) after the company reported a second death linked to its gene therapy Elevidys in a non-ambulatory Duchenne muscular dystrophy (DMD) patient.

Shares of the company are down around 35% in premarket trading. 

BMO cut its rating to Market Perform, citing heightened uncertainty, while Piper downgraded Sarepta to Neutral, saying the fatality could further disrupt uptake and commercial momentum for Elevidys.

Both brokerage noted that while the treatment remains available for ambulatory patients, broader concerns around safety and regulatory scrutiny could weigh on near-term performance.

Sarepta said over the weekend it has suspended commercial shipments of Elevidys in the non-ambulatory setting and paused dosing in its confirmatory ENVISION trial.

The company plans to implement an enhanced immunosuppressive regimen that includes sirolimus and will seek FDA approval to resume treatment.

BMO said the death, the second linked to acute liver failure in non-ambulatory patients, was not unexpected given known risks with AAV-based gene therapies, but added that the timing increases investor concerns.

Sarepta shares dropped 27% after the first death in March. BMO lowered its price target to $70, warning of risks to 2025 revenue guidance and potential regulatory action affecting non-ambulatory approval.

Piper Sandler cut its price target to $36 from $55 and slashed peak Elevidys sales estimates to $1.7 billion from $2.4 billion.

The firm said commercial use in the ambulatory population could also be negatively impacted as confidence in the therapy is reevaluated.

Sarepta is scheduled to host a conference call Monday morning to provide further details.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.